Candidatura para renovación de la Junta Directiva de GETTHI 2024- 2026

Dra. Bárbara Rivera, con DNI: 80063725N

Presento mi candidatura para optar al cargo de vocal para la renovación de la Junta Directiva de GETTHI.

VOCAL

Nombre y Apellido: Bárbara Rivera Polo
Centro: IDIBELL

During my career, I have demonstrated solid accomplishment in the discovery of novel tumor susceptibility genes and deciphering the mechanism that drives cancer susceptibility and promotes tumorigenesis to solve clinical riddles, as proved with my track record of publications. My PhD at the Familial Cancer Unit (CNIO) was focused on studying molecular genetics of polyposis patients and their clinical follow-up. This period provided me with a very comprehensive view of familial cancer patients. My postdoctoral training broadened my scope towards interrogation of rare syndromes associated to alterations in oncogenes. This led to the discovery of familial DNETs caused by FGFR1, and the characterization of oncogenic mosaic syndromes. I also acquired a strong background in the field of DNA repair associated cancers and the mechanisms driving the DNA repair impairment, uncovering the multi-tumor phenotype of NTHL1 and characterizing for the first time a pathogenic RAD51D missense variant. My training also allowed me todevelop a skillset focused on the optimization of NGS approaches to analyze archival tumors and samples with minimal quantity.

As an assistant professor at the department of Oncology of McGill University, I launched my research program in the genomics of rare hereditary tumors and their molecular biology. My research required a comprehensive approach including genomics, pathology and functional characterization, population genetics and phenotypes to understand the susceptibility driver and the phenotypic spectrum consequences. In 2020, I gained a La Caixa junior Fellowship and I moved my laboratory to the Hereditary Cancer Program of the ICO-IDIBELL. I discovered the novel DGCR8 syndrome (now recognized in the next Genetic Tumor Syndrome edition, Blue

Book, IARC-WHO) and opened a specific line of research in miRNA biogenesis associated tumorigenesis.
In 2022, I won a Miguel Servet Grant and now I lead the Rare TumorS Lab at IDIBELL that is composed of eight members with multidisciplinary backgrounds (cell biologists, geneticists, bioinformaticians and a medical doctor). Since 2018, as an independent PI, I have been extensively funded to launch my research group and I have mentored more than 15 people demonstrating. I am a member of the research taskforce 5 of the European Reference Network Genturis and member of the Scientific Program Committee of the ESHG.

Link a página web y/o PubMed:
https://hereditarycancergroup.com/team/rare-tumors-lab/

https://www.ncbi.nlm.nih.gov/myncbi/collections/mybibliography/